Table 2.
Crude OR, adjusted OR and 95 % CI of the XRCC1 polymorphisms Arg194Trp and Arg399Gln among cases and controls
| Genotypes | Cases (with SCa diagnosis), No. (%) (n = 197) | Controls, No. (%) (n = 93) | Crude OR (95 % CI) | Adjusted ORb (95 % CI) | Cases (with NMSCc diagnosis), No. (%) (n = 74) | Controls, No. (%) (n = 93) | Crude OR (95 % CI) | Adjusted ORb (95 % CI) |
|---|---|---|---|---|---|---|---|---|
| Codon 194 | ||||||||
| Arg/Arg | 93 (47.2) | 52 (55.9) | 1.0 (Reference) | 1.0 (Reference) | 34 (45.9) | 52 (55.9) | 1.0 (Reference) | 1.0 (Reference) |
| Arg/Trp | 84 (42.6) | 28 (30.1) | 1.677 (0.97–2.90) | 1.810 (1.03–3.18) | 33 (44.6) | 28 (30.1) | 1.804 (0.93–3.49) | 2.380 (1.15–4.95) |
| Trp/Trp | 20 (10.2) | 13 (14.0) | 0.860 (0.40–1.87) | 0.877 (0.40–1.94) | 7 (9.5) | 13 (14.0) | 0.914 (0.34–2.44) | 1.092 (0.38–3.11) |
| Arg/Trp + Trp/Trp | 104 (52.8) | 41 (44.1) | 1.418 (0.86–2.33) | 1.517 (0.91–2.54) | 40 (54.1) | 41 (44.1) | 1.522 (0.83–2.79) | 1.955 (1.00–3.81) |
| Codon 399 | ||||||||
| Arg/Arg | 111 (56.3) | 51 (54.8) | 1.0 (Reference) | 1.0 (Reference) | 47 (63.5) | 51 (54.8) | 1.0 (Reference) | 1.0 (Reference) |
| Arg/Gln | 61 (31.0) | 21 (22.6) | 1.335 (0.74–2.42) | 1.387 (0.75–2.56) | 21 (28.4) | 21 (22.6) | 1.090 (0.53–2.23) | 0.927 (0.44–1.98) |
| Gln/Gln | 25 (12.7) | 21 (22.6) | 0.547 (0.28–1.07) | 0.590 (0.29–1.20) | 6 (8.1) | 21 (22.6) | 0.297 (0.11–0.80) | 0.318 (0.11–0.92) |
| Arg/Gln + Gln/Gln | 86 (43.7) | 42 (45.2) | 0.941 (0.57–1.55) | 1.000 (0.60–1.67) | 27 (36.5) | 42 (45.2) | 0.694 (0.37–1.29) | 0.632 (0.33–1.23) |
OR odds ratio, CI confidence interval, SC skin cancer, NMSC nonmelanoma skin cancer
aSC includes actinic keratosis, Bowen’s disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and extramammary Paget’s disease
bAdjusted for age and sex
cNMSC includes basal cell carcinoma and squamous cell carcinoma